Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 122, Issue 4, Pages 593-606Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-014-1294-z
Keywords
Alzheimer's disease; Pioglitazone; Rosiglitazone; Tau hyperphosphorylation; Neuroinflammation; Thiazolidinediones
Categories
Funding
- New York State Office for People with Developmental Disabilities
- Alzheimer's Association [IIRG-10-170405]
Ask authors/readers for more resources
Sporadic Alzheimer's disease (AD) is a multifactorial metabolic brain disorder characterized by progressive neurodegeneration. Decreased brain energy and glucose metabolism occurs before the appearance of AD symptoms and worsens while the disease progresses. Deregulated brain insulin signaling has also been found in AD recently. To restore brain insulin sensitivity and glucose metabolism, pioglitazone and rosiglitazone, two insulin sensitizers commonly used for treating type 2 diabetes, have been studied and shown to have some beneficial effects in AD mouse models. However, the molecular mechanisms of the beneficial effects remain elusive. In the present study, we treated the 3xTg-AD mice, a widely used mouse model of AD, with pioglitazone and rosiglitazone for 4 months and studied the effects of the treatments on cognitive performance and AD-related brain alterations. We found that the chronic treatment improved spatial learning, enhanced AKT signaling, and attenuated tau hyperphosphorylation and neuroinflammation. These findings shed new light on the possible mechanisms by which these two insulin sensitizers might be useful for treating AD and support further clinical trials evaluating the efficacy of these drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available